Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1995 Oct;74(4):365–369. doi: 10.1136/hrt.74.4.365

Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction.

A Tamura 1, T Watanabe 1, Y Mikuriya 1, M Nasu 1
PMCID: PMC484039  PMID: 7488447

Abstract

OBJECTIVE--To examine the association between serum lipoprotein(a) and angiographically assessed coronary artery disease progression without new myocardial infarction. PATIENTS AND DESIGN--85 patients with coronary artery disease who underwent serial angiography with an interval of at least two years were studied. Progression of coronary artery disease was defined as an increase in diameter stenosis of 15% or more. Vessels on which angioplasty had been performed were excluded from the analysis. The patients were classified into two groups: a progression group without new myocardial infarction (n = 48) and non-progression group (n = 37). Risk factors including lipoprotein(a) were evaluated to see how they were related to progression without myocardial infarction. RESULTS--There were no differences between the two groups in the following factors: age, gender, the time interval between the angiographic studies, the distribution of the analysed coronary arteries, and history of well established coronary risk factors. Univariate analysis showed that serum lipoprotein(a) (P = 0.0002), cigarette smoking between the studies (P = 0.002), serum high density lipoprotein (P = 0.003), and serum low density lipoprotein (P = 0.01) were related to progression without myocardial infarction. Multivariate analysis selected two independent factors for progression without myocardial infarction: serum lipoprotein(a) (P = 0.003) and serum high density lipoprotein (P = 0.03). CONCLUSIONS--Serum lipoprotein(a) concentrations are closely related to the progression of coronary artery disease without new myocardial infarction. Lipoprotein(a) lowering treatment may be needed to prevent disease progression in patients with coronary artery disease and high serum lipoprotein(a).

Full text

PDF
365

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albers J. J., Marcovina S. M., Lodge M. S. The unique lipoprotein(a): properties and immunochemical measurement. Clin Chem. 1990 Dec;36(12):2019–2026. [PubMed] [Google Scholar]
  2. Armstrong V. W., Cremer P., Eberle E., Manke A., Schulze F., Wieland H., Kreuzer H., Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 1986 Dec;62(3):249–257. doi: 10.1016/0021-9150(86)90099-7. [DOI] [PubMed] [Google Scholar]
  3. Bemis C. E., Gorlin R., Kemp H. G., Herman M. V. Progression of coronary artery disease. A clinical arteriographic study. Circulation. 1973 Mar;47(3):455–464. doi: 10.1161/01.cir.47.3.455. [DOI] [PubMed] [Google Scholar]
  4. Blankenhorn D. H., Nessim S. A., Johnson R. L., Sanmarco M. E., Azen S. P., Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987 Jun 19;257(23):3233–3240. [PubMed] [Google Scholar]
  5. Carlson L. A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989 Oct;226(4):271–276. doi: 10.1111/j.1365-2796.1989.tb01393.x. [DOI] [PubMed] [Google Scholar]
  6. Dahlen G. H., Guyton J. R., Attar M., Farmer J. A., Kautz J. A., Gotto A. M., Jr Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986 Oct;74(4):758–765. doi: 10.1161/01.cir.74.4.758. [DOI] [PubMed] [Google Scholar]
  7. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  8. Hajjar K. A., Gavish D., Breslow J. L., Nachman R. L. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989 May 25;339(6222):303–305. doi: 10.1038/339303a0. [DOI] [PubMed] [Google Scholar]
  9. Hearn J. A., DeMaio S. J., Jr, Roubin G. S., Hammarstrom M., Sgoutas D. Predictive value of lipoprotein (a) and other serum lipoproteins in the angiographic diagnosis of coronary artery disease. Am J Cardiol. 1990 Nov 15;66(17):1176–1180. doi: 10.1016/0002-9149(90)91094-m. [DOI] [PubMed] [Google Scholar]
  10. Hoefler G., Harnoncourt F., Paschke E., Mirtl W., Pfeiffer K. H., Kostner G. M. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis. 1988 Jul-Aug;8(4):398–401. doi: 10.1161/01.atv.8.4.398. [DOI] [PubMed] [Google Scholar]
  11. Jauhiainen M., Koskinen P., Ehnholm C., Frick M. H., Mänttäri M., Manninen V., Huttunen J. K. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 1991 Jul;89(1):59–67. doi: 10.1016/0021-9150(91)90007-p. [DOI] [PubMed] [Google Scholar]
  12. Kostner G. M., Avogaro P., Cazzolato G., Marth E., Bittolo-Bon G., Qunici G. B. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981 Jan-Feb;38(1-2):51–61. doi: 10.1016/0021-9150(81)90103-9. [DOI] [PubMed] [Google Scholar]
  13. Maeda S., Abe A., Seishima M., Makino K., Noma A., Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 1989 Aug;78(2-3):145–150. doi: 10.1016/0021-9150(89)90218-9. [DOI] [PubMed] [Google Scholar]
  14. Marburger C., Hambrecht R., Niebauer J., Schoeppenthau M., Scheffler E., Hauer K., Schuler G., Schlierf G. Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. Am J Cardiol. 1994 Apr 15;73(11):742–746. doi: 10.1016/0002-9149(94)90874-5. [DOI] [PubMed] [Google Scholar]
  15. Moise A., Lespérance J., Théroux P., Taeymans Y., Goulet C., Bourassa M. G. Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: analysis of 313 nonoperated patients. Am J Cardiol. 1984 Dec 1;54(10):1176–1181. doi: 10.1016/s0002-9149(84)80063-6. [DOI] [PubMed] [Google Scholar]
  16. Raichlen J. S., Healy B., Achuff S. C., Pearson T. A. Importance of risk factors in the angiographic progression of coronary artery disease. Am J Cardiol. 1986 Jan 1;57(1):66–70. doi: 10.1016/0002-9149(86)90953-7. [DOI] [PubMed] [Google Scholar]
  17. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H. J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989 Sep-Oct;9(5):579–592. doi: 10.1161/01.atv.9.5.579. [DOI] [PubMed] [Google Scholar]
  18. Rhoads G. G., Dahlen G., Berg K., Morton N. E., Dannenberg A. L. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 1986 Nov 14;256(18):2540–2544. [PubMed] [Google Scholar]
  19. Ridker P. M., Hennekens C. H., Stampfer M. J. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993 Nov 10;270(18):2195–2199. [PubMed] [Google Scholar]
  20. Rosengren A., Wilhelmsen L., Eriksson E., Risberg B., Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ. 1990 Dec 1;301(6763):1248–1251. doi: 10.1136/bmj.301.6763.1248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Schaefer E. J., Lamon-Fava S., Jenner J. L., McNamara J. R., Ordovas J. M., Davis C. E., Abolafia J. M., Lippel K., Levy R. I. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention Trial. JAMA. 1994 Apr 6;271(13):999–1003. doi: 10.1001/jama.1994.03510370051031. [DOI] [PubMed] [Google Scholar]
  22. Seed M., Hoppichler F., Reaveley D., McCarthy S., Thompson G. R., Boerwinkle E., Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990 May 24;322(21):1494–1499. doi: 10.1056/NEJM199005243222104. [DOI] [PubMed] [Google Scholar]
  23. Walton K. W., Hitchens J., Magnani H. N., Khan M. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis. 1974 Sep-Oct;20(2):323–346. doi: 10.1016/0021-9150(74)90016-1. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES